Chinese biotech hamstrung by production issues
Article Abstract:
China's fast-developing biopharmaceutical industry is encountering a production bottleneck due to stricter intellectual property rules that have made drug makers less inclined to invest heavily in biotech manufacturing facilities. Experts believe that China's biotech manufacturers could still have an impact on the world market by focusing on low-cost production of micro-organism-based protein drugs, vaccines and antibodies for research and diagnostic use if they improve insurance policies, industry investment and talent training.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
When the price is right
Article Abstract:
The UK's National Institute of Clinical Excellence (NICE) has rejected a newly approved biotech drug on the grounds that it is not cost-effective. The predictive and preventive healthcare grounded on the basis of economic benefits are becoming very common and this is pressuring the biotech drug producers to think about lowering their process, particularly if they want their drug to become the treatment of choice before the arrival of cheap generic versions.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
China's biotech experiments
Article Abstract:
China's leading pharmaceutical companies are state owned and have no incentive to support the innovative drug research at a risky biotech startup. If China wants a globally competitive biotech industry, then more money and commitment is needed not just from the government but also from investors and pharma partners to bring opportunities for biotech entrepreneurs.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The first 100 days: A biotech CEO survey. Why tissue engineering needs process engineering. Does your chairman need to be a superma
- Abstracts: EARNing a way out. When one black belt is enough. J.B. Hunt Transport Services Inc
- Abstracts: Linear temporal characteristics of heart interbeat interval as an index of the pilot's perceived risk. Complete recovery time after exhaustion in high-intensity work
- Abstracts: People as prophets: liberation theology as a radical perspective on accounting. Accounting for the public interest: a Japanese perspective